`
`Page 1 of 366
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`14/493,903
`
`ISSUE DATE
`
`01/06/2015
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8927606
`
`2014-1250
`
`7395
`
`513
`
`7590
`
`12/17/2014
`
`WENDEROTH, LIND & PONACK, L.L.P.
`1030 15th Street, N.W.,
`Suite 400 East
`
`Washington, DC 20005-1503
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above—identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above—identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(S) (Please see PAIR WEB site http://pair.uspto. gov for additional applicants):
`
`Shirou SAWA, Hyogo, JAPAN;
`SENJU PHARMACEUTICAL CO., LTD., Osaka, JAPAN, Assignee (With 37 CFR 1.172 Interest);
`Shuhei FUJITA, Hyogo, JAPAN;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`Pa e 2 of 366
`IR103 (Rev.
`/09)
`
`Page 2 of 366
`
`
`
`
`
`PA RT ii ~ .l*7El4I{S} TEA NSM.IT'l‘A.L
`
`Cmnplete and send ihis fern}, mgether with étpplicalzie .l‘ee(s}, to:
`
`or
`
`Mail Stop ISSIEIEL FEE
`(.?t1n1n1iss.i0.:1e1' fur Patents
`RU. Buys: 1450
`Mexandria, Viuginia ;2:.’?.3i£ 3-1 -1517?
`(571)-273-2385
`
`fhtcmgix 5 shouid be cmnplcicd where
`l.‘>£~:n:'k.s. 1
`‘.1‘§1i,~*
`I
`iTo.:‘sn <.1u;-uE»;l Ens maxi fur u'anmnimn:z_ 1.11:‘. 15
`.1‘ Ff-iI::‘. and P1.3B1..IC.-'\’1‘It‘.)i\‘ X-*‘§E,‘:':i (if_m3ui;~;--d).
`‘J'RI?~=LT1‘I(ZI:
`‘G:
`
`
`
`
`
`
`
`
`1‘rmsk<d E5’: the, <:um'.~.r:i corr
`3n §.~F'§ zuvgl Jzmifim in of n.1;n'.n::‘mum;= 5
`,:zp§:r:_>;_>_r:.
`..
`-M ‘>l‘u:‘l1‘;-'.~‘
`emf:»..spoz':rlcz':;§s iL1ci.u»;‘ling' Iihv E
`.\\lUi. ;::h:;m
`~< viii
`Jssiiesscrg. a:‘1_:iv‘~<< as
`smicatcd xmi-3.5.3 ::os;'c:1cd h1:I»'3\=«= or dzm;'i.e:d 0t1‘n:rw1,s~. in rm-pg L by 6 :1} ‘Sf.‘ii;‘Ci§)'in}.‘,'
`:1. 112w o:.=r11:sponoI‘::m‘.«:‘. srdai:\;:;s: and.-"u;‘ {b} ind1c2:£1;;g_ 5: scyrnarzsia;
`- ADDRE:
`..
`his-r
`_«.1\aiutm1m\:%t‘ {ms am£§fic3‘Lim':s.
`—-
`1‘
`
`:33" mt
`17-‘: xased Em‘ d¢xm:s::§c mg:
`-fa c»-:néf‘§_c.2a:.:: of mz~.ii1'sas.5 L‘;-‘H1 cmh'
`
`
`}.‘tT
`1't{!etl1}"!flg
`t.>t.hE‘S' :1
`"1"Il1s.<. ct‘.:‘iifi
`lit‘ r.‘;'1.11imI hr: u5«.:‘¢i ff)
`
`
`ggmmzur my m;‘m.=:{ d;*.=n'\':,ng, must
`_ ‘
`:1: p.;;.\: ‘ ‘such as an
`gape I
`mw 115 own ::m‘E;iu:ext:~ oi‘ ;Jr..'5;iu1g, rsr Lm‘nsm1sss<:>1L
`
`
`
`
`
`
`ss maii 5'3; 311 e11V'el(up£r
`.
`f:u'.:x‘-irnd»':
`z:h:m':.
`1'14!
`ix-.‘;1\~2_‘
`_.
`.. U3’! ihe. ci:i:t€.311d\(::~11t‘.d bslow.
`
`
`
`
`V
`_
`_
`_
`_
`_
`
`r.‘:_-.::_‘.‘\t-NI um
`83‘ 2:1‘-‘r:-Kc: 9.»: :3!,.:-<5:
`
`_
`_
`:'x:q».1:4y (£m:3:: -):‘.\;:<h‘>:«3.\3
`
`s
`
` Di5{R(}'Fi;’i. i. IND Z:’()N
`
`
`
`I030 135?} Stmczt, N.W
`Suite. 490 E32251
`W:1shi:3gI(.»s1, §.){'.‘. ‘?.Ui{}{}5- £503
`
`.-\.§’I3f..iC'I.:*C§.'§(FN ?a"i'.>.
`I~'«I~.“‘¢fv.*}V_‘-_.,‘.3i‘.<L‘.
`
`1”II..ING' D.-&'I‘i.?
`C-“u“;’;'£}’rr".7;-.')} 4
`
`"ER
`
`:‘~FAi\-f".E'€‘.-E ."cN’\.":‘-‘.:\:‘-'§“'l1i%
`E‘«hir<.=Lt .‘5.~'\‘-7\".~'\
`
`‘1‘l’l‘1..Ii(‘)}" \"E;\‘}‘s‘§(.i;\‘: AQT‘ ti
`
`’;<i'i i -is 1250
`
`Z.(i)YL;J1.’I'1I:i;\5‘fl...9\ “1:;'I'IC Aliiii}
`
`".3 '3
`
`
`
`nrmps ‘ovi sional
`
`
`i.PNDE${_T(‘)1.?N‘1‘§£l‘}
`
`
`}‘_bc‘a.‘E'i‘. EISFEE‘
`
`
`€324’ I $9.120} S
`
`
`
`WE-Nfl—ER(-R-Hr “ND 3‘ Pi-EN LEL_p_
`i ——————————————————————————————————————————————————————————————————~
`7
`-—................................................................. ..
`
`3
`
`"""""""""""""""""""""""""""""""""" "
`
`‘.3. F01‘ guiuxiing; am the patani fmni gm:<;:':. 33.91?
`
`
`{1} "H19 rm/rr_;:..s at‘ up 2;’:
`'4 1'¢:gi5:,m'c:¢i palm: aEic.::m‘),\s
`or agents (JR. ;;i1m'11s:Ein~
`-
`.
`.
`_
`,
`.
`_.
`}.
`,.
`I
`'.
`_
`_
`H1, gmfng Q} 3 gjgjgig{1f1n‘kfg,5§.u\Q
`11 ;3_u;';_Ҥ_}.3j_ 3
`‘
`1.: and Sim vewes oi‘ up {0
`m ‘s 01‘£xg£:f1i9. I: no mama‘ AS
`iT3Fi1.1i8-‘=1
`
`
`
` 1
`
`'.‘}1;:s1§g;: vi." ¢‘:0lTt‘1:[.1{Jm.Ei:m.‘f: :wldm.<;s m‘ im1'u‘;s5.'Lmx of "§>’m': .:\.:'§rJ5:‘a§’ 43.?’
`{IR 14.563).
`¢
`sdcxzc-: 2u,Ex,Es":.:
`E22,‘ mimxhxrd.
`‘am-in:m1.~;:;: in
`Micim ‘ In '
`
`: {}3~~.’}2 H5’ mm-,- 5
`iii} aEr:u':E‘1cd.
`—‘
`.-;
`requin*.ri.
`
`ins" (_‘.has1gc of C '):‘i"C§}§iw'1I1i,i\;“I1€t
`
`
`
`{_‘.}1ax3gc of C95;
`.:k.ddn>:s.~: EEm11 I-“
`I
`=
`m’
`Nnmlaér
`
`
`
`~'3<;' is idcsxtjiicci bé‘im>;'_.
`
`fhxt‘ ch'>:.':\‘xrrs¢.-at $133 be-:‘;\ mad for
`
` M
`
`
`sgssec is i>(!mr5i"m§i
`f_>L*§'gn.>:,_ rm :15.
`3,1:
`’
`I
`if an
`:4»: wit! :'¢ppe;%_r ~:;m the palm}{.
`A 5;uhst1ELm‘. for is 1ms_.3 em e:ssig3,n.:u:‘.11{.
`. “R 3.11,
`(j».u11pteiIi.<r1‘ oi Ehiii {arm is N01‘
`{B} RE.-SII)}fi:\‘tiII:i: CETITY and S’.‘:‘A'§‘I:T. OR C()L=':”~é"'I'I'{Y,‘:
`
`{_.«~‘\}1 .‘:\‘..-’.k.:\'I}f:? OF Af:‘aE33I.(:‘r.:VZf:i:Z
`
`SENJU PH/~\RMACEUT§CAL CELL, LTD.
`
`Q3!-\i=‘{X3\, JAPAN
`x "
`
`i
`
`‘
`
`:"
`
`t_‘fc:;mt‘ cht‘1'}»;. the .'_t§,‘:§:l'¢‘(‘.\}‘.\1‘.1:iJ_t‘ u5;s15g,21:,~.:~,
`
`i‘.Xi.l_~':‘§__,{w‘_‘tL’_\_" m c.::.L<:g_;<_v,:.1:~.s fwd] nut ha pn,1ut*d an 131:‘: pal';~.n1'} :
`
`‘J lmfnruhml
`
`€..m‘,r_wr:1.Lmn as mixer §'.‘lfl\'&1ik‘. 531?.‘-s_I,r3 »;':.1Lt1'5-‘
`
`~..} s_mw:rmmtut
`
`-4:1.
`
`§.bi§s'.~A=.~‘iug {’cc£fs.-'} are s:u1‘::niLt:‘.d:
`férlltt‘ 1'~':‘t‘
`
`5‘
`
`-i»1\.. Vij’:£1_[v‘IikR.‘i3l 0.f'f-"»':<:(‘_§.I: {Please Kiwi reaapply any-‘ 1:11.-‘s~'inus'I§ [.m‘is§ .E=s.<-ms: {Tet .<-4.h:sws:: abnvc.-_}
`.-‘X ashtwk is 'u'rm'.f¢.v-,rr::.i.
`
`P;a.}~‘n1cn! by cm-(in. »:2u’d.~l'nr1n~'1-‘i~€Eh%>3*>5~~:~r*atrtax:htu‘:
`(:\‘-0 sm:zi1cnti1.p d§Sv;‘:”-i,I.I1L pcrn1;i!;lcd}
`1.} }’\1b1icaii:m
`
`:3 111: '\i1vs:-ct:>1‘1sh~;'n‘.h:a a_mhu:1z.u'd m_<wma1:_~c the mquiacd fvei,
`EJ Ad‘.-‘5_u,cc Ordm ~ # mi’ f.‘.npir_-s ____________________________________________ __
`_ Hacacncy. u: \m‘Li1i§ ugly
`:.n-'L<rp.a);\1\.:‘nt. ta'.1.E}v.<p»'.r.'~.sE .~’\cms1m .Mun!\.z‘1‘ _2_ €t‘l1l‘»i0Si’- 5!” ‘$743931 '~‘~‘-‘.P§r‘ 0? ml-'>‘ i0\‘m}«
`
`{,‘.h:m;;e in 3:-‘.l‘If.il§‘ Slmus ifmtu =,:£;55.L1'5 5mlin‘:s5.t'd zsbcgwi
`A.pp\i'»;2111£agcrtifivingsllicmcretii)‘ stature,
`3'3 CPR. 1.139
`
`‘
`."S\’}.§fi:?A and ‘I.‘".‘=i‘i'.‘:,
`Vt‘,
`- rxhssixt -.1 \"-Mid te:>ts'i‘1'c:‘.£iur: -*af’§e-iicm I~.’.nrii‘\_-“ mas if fort
`
`
`
`
`fer: p mem in the micm t‘mil'§= ::rm'.:sJ.m wiii mzrt int‘ 3.:
`zpiz‘:-£1 ::i U11‘ Us ui ¢I[J[.1§J"C£1{J'L‘:t1 almudmnm‘:-ni.
`G ;'\f.q'1§it'.:u3t 33-.::t'ri1s'sg .’:rr:::lI »':53LiL‘§~ .~:i:LL‘us. Sw 1'42? f.‘.H{ 1.3?‘
`:”~'£OTl’i: If tin: ::p;JIit=;xtiu11 was p:t*~:iu.1s.~'.l\- ‘Hm’!-;:::' :1m‘u:H:.nIiL3; $:.21Lus._ <.‘.I*si:.:.i;§ssg this box wiii be t.:'s.‘»-;.€n
`,...
`10 be ;n10iifiv;‘.=1IiL.‘r1l at‘ Ems 9E5i:uE§lh‘.111-2:11 in micro $n£l l‘_¢' suuus.
`5...! .-%p_plir:m1t c:I‘::\r¢;_>jr:g in I.'{‘.:>J.llm‘55.IJ.i‘1iSt'§.ii.i.IJ.l.:‘d for si.s5.v!: _
`.
`.
`H
`.
`d :1
`*1 {fl -Ackjug this box wiii he :.~\i~'.:‘1\ {Mac :1m'>‘ri5ica1ion rs£"ios'«, r:5":‘.111ir¥s;rs1¢:ss£ L0 sn\;+1§m‘mic.1'r.~
`
`D'9'ta yS'g"e :.
`1 «-
`-; a
`as appiicahitfi.
`nu
` _N{’}"H‘_’.: 1‘h;':s forrrs must. +.~is:;m in ;»1c<:<m
`
`am‘;-‘ with 3 f‘('I!‘ R.|]N§“dn$11¥A/3rfi%éB1.M:'.£ih§i§|{'Lff3z€ dz,.é tfm‘ simmisre rm :.m'c:;m;=ms am} cr:.n't.ifia=a‘ti<;vJ1s.
`
`Ch
`:nSg=WC ee @Wen em -Com,
`November 21 20’?_f§
`
`
`
`Aurfamiami $1‘g!1.'5‘I,Lkl‘&‘:
`
`
`
`
`. .at.e:20.14.].1,21.].3;Ql:Q8.:05I00'
`
`53~i“‘C
`
`T}‘pt‘.dnI‘pfinf1‘:dImifii:
`
`V‘\"V3f'FiS‘f‘£ M. Cheek
`
`f{vg1'_\':1‘::I'i<.:a1 ;\:u_
`
`Page 3 of 366
`
`}"’::gae. 2 mi‘ 3
`
`1“"'E‘(Ti-I_.v85 Part B if ‘i8‘1E'} .—'\p;:mvcd far ms: z.E1s"c>ug'h iC>f.?~1.r'2{‘.*3 3.
`
`();\-’ii-} {)s’:'5lvOO33
`
`‘P-.u=::nE sand ’I‘mdsms:r}; (bfficur: 1.3.53‘. {TIE-3}‘,.<\Is’[I’M _\‘5'{‘ 01-’ CDZX-I-.\»
`
`
`
`‘ '
`
`Page 3 of 366
`
`
`
`Electronic Patent Application Fee Transmittal
`
`T'tIe °f I'“’e"t'°"‘
`
`AQUEOUS LIQUID PREPARATION CONTAINING 2-AM|NO-3-(4-
`BROMOBENZOYL)PHENYLACETIC ACID
`
`;
`
`Utility under 35 USC111(a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD($)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-AlIowance-and-Post-Issuance:
`
`Extensaaoag-Box-ms-5
`
`Page 4 of 366
`
`
`
`Miscellaneous:
`
` S“:-S1-;(t$a)| in
`
`Total in USD (S)
`
`Page 5 of 366
`
`Page 5 of 366
`
`
`
`Electronic Acknowledgement Receipt
`
`m—
`
`T'tIe °f I'“'e"t'°"‘
`
`AQUEOUS LIQUID PREPARATION CONTAINING 2-AM|NO-3-(4-
`BROMOBENZOYL)PHENYLACETIC ACID
`
`I
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`PavmentwasWSSfu"v*eCe*vedinRAM
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)
`
`fi@gg§ itiona| Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)
`
`yes
`
`Credit Card
`
`555
`
`230975
`
`CHEEKJR., WARREN M.
`
`Page 6 of 366
`
`
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`File Listing:
`
`Document
`
`.
`
`.
`
`File Size(Bytes)/
`
`Multi
`
`Pages
`
`Issue Fee Payment (PTO-85B)
`
`AttachA_|F.pdf
`
`415516
`
`ddfl 61 7e8025bf92l e65a2b7ad884l 2e8a
`c2d1
`
`The PDF file has been signed with a digital signature and the legal effect of the document will be based on the contents of the file not the
`digital signature.
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`I363e483d9503e897c14300d4941ebc9a13
`9c76f
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`Page 7 of 366
`
`Page 7 of 366
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`513
`
`7590
`
`11/19/2014
`
`WENDEROTH, LIND & PONACK, L.L.P.
`1030 15th Street, N.W.,
`suite 400 East
`Washington, DC 20005-1503
`
`soRoUsH,LAYLA
`
`1527
`
`DATE MAILED: 11/19/2014
`
`14/493,903
`
`09/23/2014
`
`Shirou sAwA
`
`2014-1250
`
`7395
`
`TITLE OF INVENTION: AQUEOUS LIQUID PREPARATION CONTAINING 2—AMINO—3-(4—BROMOBENZOYL)PHENYLACETIC ACID
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`02/19/2015
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify Whether entitlement to that
`entity status still applies.
`
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`Page 8 of 366
`PTOL—85 (Rev. 02/11)
`
`Page 1 °f 3
`
`Page 8 of 366
`
`
`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or @ (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`p(propriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`n icated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`a i
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any Change Ofaddress)
`
`7590
`513
`WENDEROTH, LIND &
`1030 15th Street’ N'W'v
`Suite 400 East
`Washington, DC 20005-1503
`
`11/19/2014
`
`Note: A certificate of mailin can only be used for domestic mailings of the
`Fee(s) Transmittal. This certi icate cannot be used for any other accompanying
`fiapers. Each additional paper, such as an assignment or formal drawing, must
`ave its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`S(ti2(1ites Poistal Stfirvilc/E:
`suffiScé%1]tEpg]sEt]2%ge(fgr first glass mailbin an Envelope
`a
`resse
`to
`e
`a1
`top
`a
`ress a ove, or
`e1ng
`acs1m1 e
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`V
`I
`(Deposltorsname)
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`F {ST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`14/493,903
`
`09/23/2014
`
`Shirou SAWA
`
`2014- 1250
`
`7395
`
`TITLE OF INVENTION: AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`02/19/2015
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUB CLASS
`
`SOROUSH, LAYLA
`
`1627
`
`514-619000
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`
`3 Chan e of correspondence address (or Change of Correspondence
`Address orm PTO/SB/ 122) attached.
`
`2. For printing on the patent front page, list
`(1) The names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) The name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`
`
`3 "Fee Address" indication (or "Fee Address" Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Vumber is required.
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`1
`
`2
`
`3
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`'3 Individual
`
`'3 Corporation or other private group entity '3 Government
`
`4a. The following fee(s) are submitted:
`3 Issue Fee
`
`4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
`3 A check is enclosed.
`
`3 Publication Fee (No small entity discount permitted)
`3 Advance Order — # of Copies
`
`3 Payment by credit card. Form PTO-2038 is attached.
`3 The director is hereby authorized to charge the required fee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number
`(enclose an extra copy of this form).
`
`5. Change in Entity Status (from status indicated above)
`3 Applicant certifying micro entity status. See 37 CFR 1.29
`
`3 Applicant asserting small entity status. See 37 CFR 1.27
`
`3 Applicant changing to regular undiscounted fee status.
`
`NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/ 15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.
`
`Authorized Signature
`
`Typed or printed name
`
`Date
`
`Registration No.
`
`Page 9 of 366
`
`Page 2 of 3
`
`PTOL-85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB 0651-0033
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Page 9 of 366
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`F {ST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`14/493,903
`
`09/23/2014
`
`Shirou sAwA
`
`2014-1250
`
`7395
`
`WENDEROTH, LIND & PONACK, L.L.P.
`1030 15th Street, N.W.,
`Suite 400 East
`Washington, DC 20005-1503
`
`soRoUsH,LAYLA
`
`1527
`
`DATE MAILED: 11/19/2014
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`
`(Applications filed on or after May 29, 2000)
`
`The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.
`
`to eliminate the
`Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i)
`requirement that the Office provide a patent term adjustment determination with the notice of allowance. See
`Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer
`providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to
`provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant
`approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the
`patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term
`adjustment) should follow the process outlined in 37 CFR 1.705.
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of
`Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be
`directed to the Customer Service Center of the Office of Patent Publication at 1—(888)—786—0101 or (571)-272-4200.
`
`Page 10 of 366
`PTOL—85 (Rev. 02/11)
`
`Page 3 °f 3
`
`Page 10 of 366
`
`
`
`OMB Clearance and PRA Burden Statement for PTOL-85 Part B
`
`The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and
`Budget approval before requesting most types of information from the public. When OMB approves an agency
`request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration
`date for the agency to display on the instrument that will be used to collect the information and (ii) requires the
`agency to inform the public about the OMB Control Number’s legal significance in accordance with 5 CFR
`1320.5(b).
`
`The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain
`or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary
`depending upon the individual case. Any comments on the amount of time you require to complete this form
`and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT
`SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box
`1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to
`respond to a collection of information unless it displays a valid OMB control number.
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection witl1 your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant
`to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this information is
`35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which
`the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission
`related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and
`Trademark Office may not be able to process and/or examine your submission, which may result in termination of
`proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records
`may be disclosed to the Department of Justice to determine whether disclosure of these records is required
`by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance
`from the Member with respect to the subject matter of the record.
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to
`comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's
`responsibility to recommend improvements in records management practices and programs, under authority
`of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations
`governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive.
`Such disclosure shall not be used to make determinations about individuals.
`
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication
`of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the
`record was filed in an application which became abandoned or in which the proceedings were terminated
`and which application is referenced by either a published application, an application open to public
`inspection or an issued patent.
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`Page enfgrfigent agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`Page 11 of 366
`
`
`
`Application No.
`
`14/493,903
`
`App|icant(s)
`
`SAWA ET AL.
`
`LAYLA SOROUSH
`
`1627
`
`-- The MAILING DA TE of this communication appears on the cover sheet with the correspondence address--
`All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application.
`If not included
`herewith (or previously mailed), a Notice of Allowance (PTOL—85) or other appropriate communication will be mailed in due course. THIS
`NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
`of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
`
`1. IX This communication is responsive to the T.D filed on 11/5/14, 11/06/14 and approved on 11/6/14 and 11/7/14.
`
`2. I] An election was made by the applicant in response to a restriction requirement set forth during the interview on
`requirement and election have been incorporated into this action.
`
`; the restriction
`
`3. IX] The allowed cIaim(s) is/are 19-48.
`
`4. IX Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119( )—(d) or (f).
`
`a) IX All
`
`b) I:I Some*
`
`c) I:I None
`
`of the:
`
`1. I:I Certified copies of the priority documents have been received.
`
`2. IX Certified copies of the priority documents have been received in Application No. 10/525 006.
`
`3. I:I Copies of the certified copies of the priority documents have been received in this national stage application from the
`
`International Bureau (PCT Rule 17.2( )).
`
`* Certified copies not received:
`
`Applicant has THREE MONTHS FROM THE “MAILING DATE” of this communication to file a reply complying with the requirements
`noted below. Failure to timely comply will result in ABAN DONMENT of this application.
`THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
`
`5. [I A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER’S AMENDMENT or NOTICE OF
`INFORMAL PATENT APPLICATION (PTO—152) which gives reason(s) why the oath or declaration is deficient.
`
`6. I:I CORRECTED DRAWINGS ( as “replacement sheets”) must be submitted.
`(a) El including changes required by the Notice of Draftsperson’s Patent Drawing Review ( PTO—948) attached
`
`1) I:I hereto or 2) I:I to Paper No./Mail Date
`
`(b) I:I including changes required by the attached Examiner’s Amendment / Comment or in the Office action of
`Paper No./Mail Date
`Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of
`each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
`
`7. I:I DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
`attached Examiner’s comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
`
`Attachment(s)
`1. I] Notice of References Cited (PTO—892)
`
`2. I] Notice of Draftperson‘s Patent Drawing Review (PTO—948)
`
`3. IX] Information Disclosure Statements (PTO/SB/08),
`Paper No./Mail Date 10/16/14' 9/23/14
`4. I:l Examiner’s Comment Regarding Requirement for Deposit
`of Biological Material
`
`5. El Notice of Informal Patent Application
`
`6. IX Interview Summary (PTO—413),
`Paper No./Mail Date 10/22/14.
`7. IX Examiner’s Amendment/Comment
`
`8. IX Examiner’s Statement of Reasons for Allowance
`
`9. El Other
`
`.
`
`U.S. Patent and Trademark Office
`
`PTOL-37 (Rev. 03-11)
`
`Page 12 of 366
`
`Notice of Allowability
`
`Part of Paper No./Mail Date 20141106-A
`
`Page 12 of 366
`
`
`
`Application/Control Number: 14/493,903
`
`Page 2
`
`Art Unit: 1627
`
`The present application is being examined under the pre-AIA first to invent
`
`provisions.
`
`Acknowledgement of Receipt
`
`Applicant's response filed on 11/05/2014 is acknowledged.
`
`Claim Status
`
`Claims 19-48 are pending.
`
`Claims 19-48 are allowed.
`
`Withdrawn Rejections
`
`The Double Patenting rejections over U.S. Patent No. 8129431, 8497304,
`
`8669290, 8754131, 8871813, US App. No. 14502014, 14269692 is withdrawn in view of
`
`the TD’s filed on 11/05/2014 and 11/06/2014; and approved on 11/06/2014 and
`
`11/07/2014.
`
`Reasons for Allowance
`
`The following is an examiner’s statement of reasons for allowance:
`
`The method as claimed are found to be patentable over the prior art because the
`
`prior art does not teach or fairly suggest a method for treating an inflammatory disease
`
`of an eye, the method comprising administering to said eye a stable aqueous liquid
`
`preparation that comprises: (a) a first component; and (b) a second component; wherein
`
`the first component is 2—amino-3-(4— bromobenzoyl)phenylacetic acid or a
`
`pharmacologically acceptable salt thereof or a hydrate thereof, wh